Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Mantle Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (831
)
Diffuse Large B Cell Lymphoma (295
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
Non-Hodgkin’s Lymphoma (831
)
Diffuse Large B Cell Lymphoma (295
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
›
Associations
(101)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
temsirolimus
Sensitive: A1 - Approval
temsirolimus
Sensitive
:
A1
temsirolimus
Sensitive: A1 - Approval
temsirolimus
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive: A2 - Guideline
venetoclax + ibrutinib
Sensitive
:
A2
venetoclax + ibrutinib
Sensitive: A2 - Guideline
venetoclax + ibrutinib
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + ibrutinib + lenalidomide
Sensitive: A2 - Guideline
rituximab + ibrutinib + lenalidomide
Sensitive
:
A2
rituximab + ibrutinib + lenalidomide
Sensitive: A2 - Guideline
rituximab + ibrutinib + lenalidomide
Sensitive
:
A2
ALK negative
Mantle Cell Lymphoma
ALK negative
Mantle Cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
VR-CAP
Sensitive: A2 - Guideline
VR-CAP
Sensitive
:
A2
VR-CAP
Sensitive: A2 - Guideline
VR-CAP
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-DHAP
Sensitive: A2 - Guideline
R-DHAP
Sensitive
:
A2
R-DHAP
Sensitive: A2 - Guideline
R-DHAP
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-DHAX
Sensitive: A2 - Guideline
R-DHAX
Sensitive
:
A2
R-DHAX
Sensitive: A2 - Guideline
R-DHAX
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-CVAD
Sensitive: A2 - Guideline
R-CVAD
Sensitive
:
A2
R-CVAD
Sensitive: A2 - Guideline
R-CVAD
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-GemOx
Sensitive: A2 - Guideline
R-GemOx
Sensitive
:
A2
R-GemOx
Sensitive: A2 - Guideline
R-GemOx
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: A2 - Guideline
rituximab + ibrutinib
Sensitive
:
A2
rituximab + ibrutinib
Sensitive: A2 - Guideline
rituximab + ibrutinib
Sensitive
:
A2
CCR7 positive
Mantle Cell Lymphoma
CCR7 positive
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: B - Late Trials
brexucabtagene autoleucel
Sensitive
:
B
brexucabtagene autoleucel
Sensitive: B - Late Trials
brexucabtagene autoleucel
Sensitive
:
B
ABCB1 mutation + VEGFA mutation
Mantle Cell Lymphoma
ABCB1 mutation + VEGFA mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
VEGFA mutation
Mantle Cell Lymphoma
VEGFA mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
ABCB1 mutation
Mantle Cell Lymphoma
ABCB1 mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
INCB50465
Sensitive: B - Late Trials
INCB50465
Sensitive
:
B
INCB50465
Sensitive: B - Late Trials
INCB50465
Sensitive
:
B
CCND1 overexpression
Mantle Cell Lymphoma
CCND1 overexpression
Mantle Cell Lymphoma
INCB50465
Sensitive: C2 – Inclusion Criteria
INCB50465
Sensitive
:
C2
INCB50465
Sensitive: C2 – Inclusion Criteria
INCB50465
Sensitive
:
C2
TP53 mutation
Mantle Cell Lymphoma
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C2 – Inclusion Criteria
rituximab + ibrutinib
Sensitive
:
C2
rituximab + ibrutinib
Sensitive: C2 – Inclusion Criteria
rituximab + ibrutinib
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
